Search Result
Results for "
folate receptors
" in MedChemExpress (MCE) Product Catalog:
10
Biochemical Assay Reagents
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-13728
-
ZD 9331; BGC9331
|
Thymidylate Synthase
|
Cancer
|
Plevitrexed (ZD 9331; BGC 9331) is an orally active and potent thymidylate synthase (TS) inhibitor with a Ki of 0.44 nM. Plevitrexed is taken up via the α-folate receptor as well as the reduced folate carrier. Plevitrexed is used for gastric cancer in clinical . Plevitrexed is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-P99612
-
MORAb-202
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
|
-
-
- HY-10822A
-
BGC 945 trisodium; Idetrexed trisodium; CB 300945 trisodium
|
Thymidylate Synthase
|
Cancer
|
ONX 0801 (BGC 945) trisodium is a thymidylate synthase (TS) inhibitor, targeted to α-folate receptor–overexpressing tumors .
|
-
-
- HY-147699
-
|
Antifolate
|
Cancer
|
FRα-IN-1 (Compound 4) is a tumor-targeting agent. FRα-IN-1 shows selective anticancer activity towards folate receptors (FRα and FRβ) expression cells .
|
-
-
- HY-115873
-
|
PROTACs
|
Cancer
|
Folate-MS432, a PROTAC, is capable of degrading MEKs in a folate receptor-dependent manner in cancer cells.
|
-
-
- HY-144009
-
|
Liposome
|
Cancer
|
DSPE-PEG-Folate, MW 3350 is a PEG derivative containing folic acid. DSPE-PEG-Folate has a targeting effect and bind to folate receptors in cancer cells. DSPE-PEG-Folate form micelles/lipid bilayer and can be used to targeted drug delivery system research .
|
-
-
- HY-W440888
-
|
Liposome
|
Others
|
DSPE-PEG-Folate, MW 2000 is a PEG derivative containing folic acid. DSPE-PEG-Folate, MW 2000 has a targeting effect and bind to folate receptors in cancer cells. DSPE-PEG-Folate, MW 2000 form micelles/lipid bilayer and can be used to targeted drug delivery system research.
|
-
-
- HY-W440890
-
|
Liposome
|
Cancer
|
DSPE-PEG-Folate, MW 5000 is a PEG derivative containing folic acid. DSPE-PEG-Folate, MW 5000 has a targeting effect and bind to folate receptors in cancer cells. DSPE-PEG-Folate, MW 5000 form micelles/lipid bilayer and can be used to targeted drug delivery system research .
|
-
-
- HY-155880
-
mPEG-NH2 (MW 350)
|
Liposome
|
Cancer
|
mPEG-amine (MW 350) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
-
-
- HY-155881
-
mPEG-NH2 (MW 550)
|
Liposome
|
Cancer
|
mPEG-amine (MW 550) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
-
-
- HY-155882
-
mPEG-NH2 (MW 750)
|
Liposome
|
Cancer
|
mPEG-amine (MW 750) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
-
-
- HY-155883
-
mPEG-NH2 (MW 3400)
|
Liposome
|
Cancer
|
mPEG-amine (MW 3400) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
-
-
- HY-155884
-
mPEG-NH2 (MW 4000)
|
Liposome
|
Cancer
|
mPEG-amine (MW 4000) can be used to synthesize folate-conjugated polymer micelles for encapsulating anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
-
-
- HY-P99225
-
M9346A
|
Antifolate
|
Cancer
|
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
|
-
-
- HY-128939
-
|
Antifolate
|
Cancer
|
EC0488 is used to synthesize EC0531 with folate receptor (FR)-specific and anti-tumor activities .
|
-
-
- HY-W115607
-
Poly(ethylene glycol)-bis-amine (MW 8000)
|
Liposome
|
Cancer
|
PEG-bis-amine (MW 8000) synthesizes folate-conjugated polymeric micelles for encapsulation of the anticancer agent 9-nitrocamptothecin HY-16560 (HY-16560). Folic acid-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
-
-
- HY-W591632
-
Poly(ethylene glycol)-bis-amine (MW 1000)
|
Liposome
|
Cancer
|
PEG-bis-amine (MW 1000) synthesizes folate-conjugated polymeric micelles for encapsulation of the anticancer agent 9-nitrocamptothecin HY-16560 (HY-16560). Folic acid-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
-
-
- HY-114306
-
|
Antifolate
|
Cancer
|
EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor . Small molecule-agent conjugate (SMDC) .
|
-
-
- HY-10822
-
BGC 945; ONX-0801
|
Thymidylate Synthase
|
Others
|
Idetrexed is a thymidylate synthase inhibitor specifically transported into alpha-folate receptor (alpha-FR)-overexpressing tumors. BGC 945 inhibited thymidylate synthase with a Ki of 1.2 nmol/L .
|
-
-
- HY-13615A
-
|
Fluorescent Dye
|
Cancer
|
EC-17 (disodium salt) is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum. The peak excitation and emission wavelengths of EC-17 are 470/520 nm.
|
-
-
- HY-P99153
-
MORAb-003
|
Antibiotic
|
Cancer
|
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
|
-
-
- HY-D1716
-
|
Fluorescent Dye
|
Cancer
|
S0456 is a near-infrared (NIR) fluorescent dye that can be used for synthesize Pafolacianine (HY-139579). S0456 binds to the folate receptor (FR). S0456 can be used as a tumor-specific optical imaging agent. The excitation wavelength is 788 nM and emission wavelength is 800 nM .
|
-
-
- HY-132258
-
IMGN853
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Mirvetuximab soravtansine (IMGN853) is an antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .
|
-
-
- HY-132258A
-
IMGN853 (solution)
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Mirvetuximab soravtansine (IMGN853) solution is an antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .
|
-
-
- HY-148194
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
SC239 is a cleavable 2-aminophenyl hemiasterlin agent-linker. SC239 can be as the agent-linker for ADC . SC239 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
Cat. No. |
Product Name |
Type |
-
- HY-144009
-
|
Drug Delivery
|
DSPE-PEG-Folate, MW 3350 is a PEG derivative containing folic acid. DSPE-PEG-Folate has a targeting effect and bind to folate receptors in cancer cells. DSPE-PEG-Folate form micelles/lipid bilayer and can be used to targeted drug delivery system research .
|
-
- HY-W440888
-
|
Drug Delivery
|
DSPE-PEG-Folate, MW 2000 is a PEG derivative containing folic acid. DSPE-PEG-Folate, MW 2000 has a targeting effect and bind to folate receptors in cancer cells. DSPE-PEG-Folate, MW 2000 form micelles/lipid bilayer and can be used to targeted drug delivery system research.
|
-
- HY-W440890
-
|
Drug Delivery
|
DSPE-PEG-Folate, MW 5000 is a PEG derivative containing folic acid. DSPE-PEG-Folate, MW 5000 has a targeting effect and bind to folate receptors in cancer cells. DSPE-PEG-Folate, MW 5000 form micelles/lipid bilayer and can be used to targeted drug delivery system research .
|
-
- HY-155880
-
mPEG-NH2 (MW 350)
|
Drug Delivery
|
mPEG-amine (MW 350) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
-
- HY-155881
-
mPEG-NH2 (MW 550)
|
Drug Delivery
|
mPEG-amine (MW 550) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
-
- HY-155882
-
mPEG-NH2 (MW 750)
|
Drug Delivery
|
mPEG-amine (MW 750) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
-
- HY-155883
-
mPEG-NH2 (MW 3400)
|
Drug Delivery
|
mPEG-amine (MW 3400) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
-
- HY-155884
-
mPEG-NH2 (MW 4000)
|
Drug Delivery
|
mPEG-amine (MW 4000) can be used to synthesize folate-conjugated polymer micelles for encapsulating anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
-
- HY-W115607
-
Poly(ethylene glycol)-bis-amine (MW 8000)
|
Drug Delivery
|
PEG-bis-amine (MW 8000) synthesizes folate-conjugated polymeric micelles for encapsulation of the anticancer agent 9-nitrocamptothecin HY-16560 (HY-16560). Folic acid-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
-
- HY-W591632
-
Poly(ethylene glycol)-bis-amine (MW 1000)
|
Drug Delivery
|
PEG-bis-amine (MW 1000) synthesizes folate-conjugated polymeric micelles for encapsulation of the anticancer agent 9-nitrocamptothecin HY-16560 (HY-16560). Folic acid-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99612
-
MORAb-202
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
|
-
- HY-P99225
-
M9346A
|
Antifolate
|
Cancer
|
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
|
-
- HY-P99153
-
MORAb-003
|
Antibiotic
|
Cancer
|
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
|
Cat. No. |
Product Name |
|
Classification |
-
- HY-13728
-
ZD 9331; BGC9331
|
|
Alkynes
|
Plevitrexed (ZD 9331; BGC 9331) is an orally active and potent thymidylate synthase (TS) inhibitor with a Ki of 0.44 nM. Plevitrexed is taken up via the α-folate receptor as well as the reduced folate carrier. Plevitrexed is used for gastric cancer in clinical . Plevitrexed is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-148194
-
|
|
DBCO
|
SC239 is a cleavable 2-aminophenyl hemiasterlin agent-linker. SC239 can be as the agent-linker for ADC . SC239 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
|
-
- HY-10822A
-
BGC 945 trisodium; Idetrexed trisodium; CB 300945 trisodium
|
|
Alkynes
|
ONX 0801 (BGC 945) trisodium is a thymidylate synthase (TS) inhibitor, targeted to α-folate receptor–overexpressing tumors .
|
-
- HY-10822
-
BGC 945; ONX-0801
|
|
Alkynes
|
Idetrexed is a thymidylate synthase inhibitor specifically transported into alpha-folate receptor (alpha-FR)-overexpressing tumors. BGC 945 inhibited thymidylate synthase with a Ki of 1.2 nmol/L .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: